· Scale up early infant diagnosis

· Scale up early infant diagnosis

Detection of HIV infection in infants is crucial so that antiretroviral therapy can be started as quickly as possible. However, it is currently very difficult to test HIV in children under 18 months due to the persistence of maternal antibodies that are present for the first 18 months of the child’s life. Currently, the only way to test children under 18 months is to use a polymerase chain reaction (PCR) machine, which is a complex DNA-based diagnostic tool.

The PCR machine is expensive, requires trained परसोंnnel and advanced laboratory infrastructures – all factors that make it difficult for national programmes to use. Additionally the machines often only exist at the centralised laboratory level which means that tests carried out in rural areas need to be sent to a central structure, and the results sent back again, a process which can take between one to three months, during which time there is the risk of losing the patient to follow up. What is needed is a test that allows the mother to be informed about her baby’s HIV status within a day.

But until a more practical long term solution is found, relying on PCR remains the only option for diagnosing children under 18 months, and as such, every effort should be made by donors and implementers to ensure that it is available and used.

· Treatment – painfully slow progress

Today there remains, despite some progress, a wide gap between the range of treatment options available for adults and those for children. Of the 22 drugs approved by the U.S. Food and Drug Administration and available for adults, six do not have paediatric indications, and seven do not exist in paediatric formulations.

Drug companies were very slow to design treatments specifically formulated for children. The first paediatric fixed-dose combination (an FDC simplifies treatment by combining several drugs in one pill) to be approved by the World Health Organization (WHO), appeared six years after the adult ones. Currently there are only seven paediatric FDCs that have been quality assured by WHO or the USFDA (US Food and Drug Administration) compared with 60 for adults

Many more drugs for children could potentially exist but it is taking a painfully long time for these drugs to be studied for use on children. This process needs to be accelerated – at the moment there are simply not enough treatment options for children. If a child should develop resistance to a class of antiretrovirals there are not enough alternative medicines available, even though these drugs exist for adults.

Additionally, what is urgently needed is a good treatment for young children co-infected with tuberculosis (TB), the most common opportunistic infection in HIV. For example, efavirenz – an antiretroviral that has been registered in the U.S. since 1998 – still has no safety or efficacy data for its use in children under three. Efavirenz is particularly needed for children with HIV/AIDS who are co-infected with TB because it does not interact with TB drugs. However, until the drug is tested on children we are not able to use it.

· Not adapted to real life conditions

Of the limited number of antiretrovirals to treat HIV that do exist for children, many of them are ill-adapted to the context where the majority of HIV infected children live. Some of them are syrups that come with logistical constraints as they are heavy or require refrigeration, others are powders that need to be mixed with clean water, all factors that make them harder to use in remote settings. Other formulations have an unpleasant taste making it harder to dispense to children. When producing paediatric drugs more thought needs to be given to where those drugs will be used, and by whom.


Ensuring that children with HIV/AIDS are no longer neglected requires:

· Boosting diagnosis: more effort and funds to be placed on diagnosing children under 18 months so that treatment can be started as soon as possible
· Improving treatment: governments and other actors to start treating more paediatric HIV patients
· Accelerating drug studies for paediatric treatments: children need more treatment options to be available sooner
· Putting the constraints that exist in remote settings at the centre of the development of paediatric HIV formulations